N
NEOGAP Therapeutics
Biotech & Life Sciences · Stockholm, Sweden · Founded 2016
Imagine if cancer patients who lack efficient treatment options could be cured MoreLess
Developer of personalized cancer immunotherapy designed to precisely target and eliminate cancer. The company's product identifies optimal neoantigens to target, activate and multiply T-lymphocytes with the purpose of eradicating cancer, enabling cancer patients to recover from the disease. Keywords: Pharmaceuticals and Biotechnology, Biopharmaceutical Producer, Biopharmaceutical Research, Cancer Cure Therapy, Immune System, Immuno-Oncology Drugs, Immunotherapy Drugs, Pharmaceutical, Pharmaceutical Medicine.
Company overview
NEOGAP Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Stockholm, Sweden
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 60.8
- Investment activity
- 1 companies · latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
NEOGAP Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Feb 2026 | $11M | $42M | Sciety | ↗ |
| GRANTOther financing | Mar 2024 | $605K | — | Undisclosed | ↗ |
| EARLY VCOther financing | Nov 2023 | $6.5M | $26M | Sciety | ↗ |
| GRANTOther financing | Mar 2023 | $2.5M | — | European Innovation Council | — |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $3.7M | 0% | 26 |
| 2025 | $3.7M | 0% | 26 |
| 2024 | $3.7M | -1.9% | 27 |
| 2023 | $3.8M | +56.2% | 24 |
| 2022 | $2.4M | +6.2% | 18 |
| 2021 | $2.3M | -18.4% | — |
| 2020 | $2.8M | — | — |
Growth signals
NEOGAP Therapeutics website traffic
Latest recorded traffic for NEOGAP Therapeutics is 590 monthly website visits, up 293.3% over the last three months. NEOGAP Therapeutics's team grew 0% over the past year.
Comparisons
NEOGAP Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
NEOGAP Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
NEOGAP Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on NEOGAP Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where NEOGAP Therapeutics has talent and traffic
team presence
In the news
Latest news about NEOGAP Therapeutics
Recent press, funding announcements, and product moves mentioning NEOGAP Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about NEOGAP Therapeutics
An AI-synthesized read of the highest-engagement posts about NEOGAP Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NEOGAP Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.